Interestingly, we found that rosiglitazone can decrease the invasion and metastatic ability of FABP4-deficient GC cells in a dose- and time-dependent manner by upregulating CADM3 expression both in vitro and in vivo. The gene discussed is CADM3; the disease is gastric cancer.